Better prospects for diagnostic test reimbursement in Germany
This article was originally published in Clinica
Executive Summary
Germany's diagnostics industry association (VDGH) has welcomed the recently-expressed view of the federal government that the inclusion of medical procedures in the reimbursement catalogue of the statutory sickness funds (GKV) should be simpler and more transparent. "Should this sentiment become a hard-and-fast decision, there would be hope that new lab tests will also, finally, be made available to those with sickness insurance," said the Frankfurt-based association's chairman, Volker Oeding.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.